文献速递生殖医学产科

胞浆内单精子注射前使用磁激活细胞分选处理精液对产科和围产结局安全:一项回顾性多中心研究

Semen processing using magnetic-activated cell sorting before ICSI is deemed safe for obstetric and perinatal outcomes: a retrospective multicentre study.
PubMed 文献 · Reprod Biomed Online · 2023-02-01

这项回顾性多中心队列研究纳入2008年1月至2020年2月供卵或自体卵母细胞的胞浆内单精子注射周期,比较标准精液处理与加用磁激活细胞分选。供卵周期评估25,356次分娩(单胎20,439),自体卵周期19,703次分娩(单胎15,917)。两组主要产科和围产疾病无显著差异,但磁激活细胞分选组妊娠期贫血发生率显著升高,供卵周期早产和极早产率显著降低。

要点

  • 供卵和自体卵周期中,加用磁激活细胞分选与标准精液处理的主要产科和围产疾病无显著差异。
  • 磁激活细胞分选组妊娠期贫血发生率显著升高(供卵P=0.01;自体卵P<0.001),但在一般人群估计患病率范围内。
  • 供卵周期中磁激活细胞分选组早产(P=0.02)和极早产(P=0.01)出生率显著降低。

核心结论

  • 胞浆内单精子注射前精液处理时使用磁激活细胞分选,对供卵或自体卵周期中母亲和新生儿孕期及分娩期间的健康似乎安全。
  • 建议未来密切随访这些参数,尤其是贫血,以检测更小的效应量。

研究设计与样本

  • 回顾性多中心队列研究,纳入2008年1月至2020年2月接受供卵或自体卵母细胞胞浆内单精子注射周期的患者。
  • 分为标准精液处理组(参考组)和加用磁激活细胞分选组(磁激活细胞分选组)。
  • 供卵周期评估25,356次分娩(单胎20,439),自体卵周期评估19,703次分娩(单胎15,917)。
  • 所有均值、率和发生率均按每个研究组每名活产新生儿计算。

主要发现

  • 供卵或自体卵周期中,两组影响母亲和新生儿健康的主要产科和围产疾病无显著差异。
  • 磁激活细胞分选组妊娠期贫血发生率显著升高(供卵P=0.01;自体卵P<0.001),但该发生率在一般人群妊娠期贫血估计患病率范围内。
  • 供卵周期中磁激活细胞分选组早产出生率显著降低(P=0.02),极早产出生率显著降低(P=0.01)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文建议未来密切随访这些参数,尤其是贫血,以检测更小的效应量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is magnetic-activated cell sorting (MACS) a safe semen sample processing technique for newborns and mothers when used for semen processing prior to intracytoplasmic sperm injection (ICSI) cycles? DESIGN: This retrospective multicentre cohort study involved patients undergoing ICSI cycles with either donor or autologous oocytes from January 2008 to February 2020. They were divided into two groups: those who underwent standard semen preparation (reference group) and those who had an added MACS procedure (MACS group). A total of 25,356 deliveries were assessed in the case of cycles using donor oocytes, and 19,703 deliveries from cycles using autologous oocytes. Of these, 20,439 and 15,917, respectively, were singleton deliveries. Obstetric and perinatal outcomes were retrospectively assessed. All means, rates and incidences were computed per live newborn in each study group. RESULTS: There were no significant differences between the main obstetric and perinatal morbidities affecting the mothers' and newborns' well-being between groups using either donated or autologous oocytes. There was a significant increase in the incidence of gestational anaemia in both subpopulations (donor oocytes P = 0.01; autologous oocytes P < 0.001). However, this incidence was within the estimated prevalence for gestational anaemia in the general population. There was a statistically significant decrease in preterm (P = 0.02) and very preterm (P = 0.01) birth rates in the MACS group in cycles using donor oocytes. CONCLUSIONS: The use of MACS during semen preparation before ICSI using either donor or autologous oocytes appears to be safe for the mothers' and newborns' well-being during pregnancy and birth. Nevertheless, a close follow-up of these parameters in the future is advised, especially concerning anaemia, in order to detect even smaller effect sizes.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Gil Juliá M, Hervas I, Navarro-Gomezlechon A, et al. Semen processing using magnetic-activated cell sorting before ICSI is deemed safe for obstetric and perinatal outcomes: a retrospective multicentre study. Reprod Biomed Online. 2023. PMID: 37244866. doi:10.1016/j.rbmo.2023.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。